Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1995-01-12
1997-10-28
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
4242031, 4242341, 4242441, 4242561, 514 54, 5361231, A61K 39385, A61K 39116, A61K 3902, A61K 3909
Patent
active
056815700
ABSTRACT:
Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a Streptococcus strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from Streptococcus pneumoniae are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than Streptococcus also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the Streptococcus strain and preferably also the Haemophilus strain. The conjugate molecules and antibodies specific for the capsular polysaccharide or specific for the outer membrane protein may be employed in diagnostic procedures and kits. A process for individually isolating P1, P2 and P6 outer membrane proteins from a Haemophilus strain also is provided.
REFERENCES:
patent: 5141743 (1992-08-01), Schryvers
Austrian, R. 1987. Pneumococcal infections. In Harrison's Principles of Internal Medicine. 11th ed. E. Braunwald, K.J. Isselbacher, R.G. Petersdorf, J.D. Wilson, J.B. Martin, and A.S. Fauci (ed), McGraw-Hill, New York. 533-537.
Chommaitree, T., and V.M. Howie. 1987. Bacteriology of otitis media. pp. 231-247. In J. Berstein and P. Ogra (ed.), Immunology of the ear. Reven Press, New York.
Giebink, G.S. 1989. The microbiology of otitis media. Pediatr. Infect. Dis. J. 8:518-520.
Austrian, R. 1981. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev. Infect. Dis. 3 (suppl):S1-S17.
Chu, C.Y., R. Schneerson, J.B. Robbins, and S.C. Rastogi. 1983. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 40:245-256.
Schneerson, R., L. Levi, J.B. Robibin, D.M. Bryla, G. Schiffman, and T. Lagergard. 1992. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect. Immun. 60:3528-3532.
Fattom, A., C. Lue, S.C. Szu, J. Mestecky, G. Schiffman, D. Bryla, W.F. Vann, D. Watson, J.B. Robbins, and R. Schneerson. 1990. Immune response in adult volunteers elicited by injection of the Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphteria toxoid. Infec. Immun. 58:2309-2312.
Robbins, J.B., R. Austrian, C.-J. Lee, S.C. Rastogi, G. Schiffman, J. Henrichsen, P.H. Makela, C.V. Broome, R.R. Facklam, R.H. Tiesjema, and J.C. Parke, Jr. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148: 1136-1159.
Shapiro, E.D., A.T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Margolis, R.K. Adair, and J.D. Clemens. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325: 1453-1460.
Sarnaik S., J. Kaplan, G. Schiffman, D. Bryla, J.B. Robbins, R. Scheerson. 1990. Studies on pneumococcus vaccine alone or mixed with DT and on pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in 2-to 5-year old children with sikle cell anemia. Pediatr. Infec. Dis. J. 9:181-186.
Weinberg, G.A., D.A. Towler, and R.S. Munson, Jr. 1988. Lipoproteins of Haemophilus influenzae type b. J. Bacterol. 170:4161-4164.
Murphy, T.F., M.B. Nelson, K.C. Dudas, J.M. Mylotte, and M.A. Apicella. 1985. Identification of a specific epitope of Haemophilus influenzae on a 16,600-dalton outer membrane protein. J. Infec. Dis. 152:1300-1307.
Murphy, T.F., L.C. Bartos, A.M. Campagnari, M.B. Nelson, K.C. Dudas, and M.A. Apicella. 1986. Identification of a 16,600 dalton outer membrane protein of nontypeable Haemophilus influenzae as a target for human bactericidal antibody. J. Clin. Invest. 78:1020-1027.
Greeen, B.A., T. Quinn-Dey, and G.W. Zlotnick. 1987. Biologic activities of antibody to a peptidoglycan-associated lipoprotein of Haemophilus influenzae against multiple clinical isolates of H. influenzae type b. Infect. Immun. 55:2878-2883.
Munson, R.S. Jr., and D.M. Granoff. 1985. Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae type b. Infect. Immun. 49:544-549.
Bradford, M.M. 1976. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
Dubois, M., K.A. Gulles, J.K. Hamilton, P.A. Rebers, and F. Smith. 1956. Colorimetric method for the determination of sugars and related substances. Anal. Chem. 28:350-356.
Panezutti, H., O. James, E.J. Hansen, Y. Choi, R.E. Harkness, M.H. Klein and P. Chong. 1993. Identification of surface-exposed B-cell epitopes recognized by Haemophilus influenzae type b P1-specific monoclonal antibodies. Infec. Immun. 61: 1867-1872.
Lockhoff, O. Glycolipids as Immunomodulators: Synthesis and Properties. 1991. Chem. Int. Ed. Engl. 30:1611-11620.
Nixon-George, A., Moran, T., Dionne, G., Penney, C.L., Lafleur, D., Bona, C.A. The adjuvant effect of stearyl tyrosine on a recombinant subunit hepatitis B surface antigen. 1990 J. Immunol. 144: 4798-4802.
Wiesmuller, K.-H., Jung, G., Hess, G. Novel low-molecular weight synthetic vaccine against foot-and mouth disease containing a potent B-cell and macrophage activator. 1989. Vaccine 8:29-33.
Deres, et al. 1989, Letters to Nature, In Vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine, vol. 342: 561-564.
Jennings, H.J. Capsular Polysaccharides as Vaccine Candidates. 1990. Current Topics in Microbiology and Immunology 150:97-127.
Porro et al 1983, Immunoelectrophoretic characterization of the molecular weight polydispersion of polysaccharides in multivalent bacterial capsular polysaccharide vaccines, J. Biol. Stand. 11: 65-74.
Brodeur, B.R., P.S. Tsang, J. Hamel, Y. Larose, S. Montplaisir. 1986. Mouse models of infection for Neisseria meningitidis B, 2b and Haemophilus influenzae type b diseases. Can. J. Microbiol. 32:33-37.
Deich, R.A., B.J. Metcalf, C.W. Finn, J.E. Farley, and B.A. Green. 1988. Cloning of genes encoding a 15,000-dalton peptidoglycan-associated lipotrotein from Haemophilus influenzae. J. Biol. Chem. 170:489-498.
Zlotnick, G.W., V.T. Sanfilippo, J.A. Mattler, D.H. Kirkley, R.A. Boykins, and R.C. Seid, Jr. 1988. Purification and characterization of a peptidoglycan-associated lipoprotein from Haemophilus influenzae, J. Biol. Chem. 263:9790-9794.
Fahim Raafat Emil Fahmy
Gisonni Lucy
Kandil Ali
Klein Michel Henri
Yang Yan-Ping
Connaught Laboratories Limited
Housel James C.
Shaver Jennifer
LandOfFree
Immunogenic conjugate molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic conjugate molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic conjugate molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1024304